Page last updated: 2024-09-05

sorafenib and cgp 57380

sorafenib has been researched along with cgp 57380 in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(cgp 57380)
Trials
(cgp 57380)
Recent Studies (post-2010) (cgp 57380)
6,5207305,25164044

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)cgp 57380 (IC50)
Serine/threonine-protein kinase Sgk1Homo sapiens (human)2.7
Dual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)3.2
Cytochrome P450 1A2Homo sapiens (human)1.6
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)2.5
Eukaryotic translation initiation factor 4EHomo sapiens (human)3
Cytochrome P450 2D6Homo sapiens (human)1.6
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)5
Casein kinase I isoform deltaHomo sapiens (human)0.51
Serine/threonine-protein kinase BRSK2Homo sapiens (human)1.1
Aurora kinase BHomo sapiens (human)2.5
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)1.2182
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)2.06

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Guan, L; Huang, M; Li, B; Li, D; Liu, B; Liu, D; Wang, S; Zang, J; Zhao, L1

Other Studies

2 other study(ies) available for sorafenib and cgp 57380

ArticleYear
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
    Bioorganic & medicinal chemistry, 2018, 09-01, Volume: 26, Issue:16

    Topics: Amides; Antineoplastic Agents; Benzofurans; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Intracellular Signaling Peptides and Proteins; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Structure-Activity Relationship

2018